Navigation Links
Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model

DENVER, Aug. 9, 2012 /PRNewswire/ -- Pharmatech Oncology announces the award of its phase 2 Small Business Innovative Research (SBIR) project, entitled A Patient Centered Approach to Enrolling Rare Cancer Patients in Clinical Trials, to be funded through the National Cancer Institute (NCI).

Pharmatech Oncology has developed an innovative enrollment methodology called Just-In-Time (JIT) to improve enrollment rates into cancer clinical trials, which often see significant delays due to slow patient enrollment.  The major challenge in developing more effective anti-cancer drugs is the time it takes to complete clinical trials demonstrating the safety and efficacy of investigational new drugs. With only an estimated 3 to 5 percent of adult cancer patients participating in clinical trials, and potentially even fewer being offered the opportunity, JIT provides patients with on-demand access to cancer clinical trials and investigational treatments.

In Phase 1 of the SBIR project, Pharmatech Oncology demonstrated that cancer trial enrollment rates can be increased by making specific clinical trials available to a network of research ready centers (Click this link to see the abstract: The JIT enrollment model puts patients first in the research process, prioritizing selection of the most appropriate therapy, and utilizing highly efficient workflow to enroll individual cancer patients into a trial in 10 days or less.

The Phase 2 project addresses the scalability of the JIT enrollment methodology as an industry-wide solution, but even more exciting is its focus on aligning patient genetic and molecular characteristics with personalized therapy. The principal investigator of the project, Dr. Matthew Wiener, believes, "The JIT enrollment methodology is ideally positioned to support the development of targeted cancer medicine by helping oncologists to select the right drugs for the right patients at the right time.

"With the continued support of the NCI through the SBIR program, Pharmatech Oncology is now positioned to advance this innovative approach in partnership with the other stakeholders in cancer research: the trial sponsors, research and advocacy organizations, the hematology-oncology professional community, and most of all cancer patients," said Dr. Wiener. "We want every cancer patient to have the best treatment options, including these advanced clinical trials."

About Pharmatech Oncology, Inc.:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Contract Research Organization (CRO) that specializes in creating efficiency in cancer clinical trials. We provide a patient centered approach for the investigational treatment of cancer by organizing and directing the entire research process, from start to finish.

For more information about Pharmatech, please visit

The project described is supported by Award Number R44CA144362 from the National Cancer institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

SOURCE Pharmatech Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Announces First-Quarter 2012 Results
2. Industry Leading Pharmaceutical News Website Refocused and Relaunched
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Champions Oncology Reports Resignation Of Director
5. Center for Medicare & Medicaid Innovation Awards $19 Million Grant to Develop Oncology Medical Home Model
6. Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities
7. Radiation Therapy in Oncology Drug Pipeline Update 2012
8. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
9. Schulman Associates IRB offers oncology-focused review board
10. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
11. Velos, Inc. Introduces Mobile App for Oncology Adverse Events and Graft-Versus-Host Disease at 2012 ASCO Annual Meeting
Post Your Comments:
(Date:11/26/2015)... UTRECHT, the Netherlands , November 26, 2015 /PRNewswire/ ...   A new combination approach blends immunotherapy ... --> A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with ... the Netherlands has found that immunotherapy ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ( ... "Advanced Wound Care Market by Type (Dressings, Therapy Devices, ... (In-Patient Facility, Out-Patient Facility), and Geography - Global Forecast ... --> --> The purpose ... and forecast of the global advanced wound care market. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... through sharing, the 2016 Building Better Radiology Marketing Programs meeting will ... on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... innovative online platform for mental health and wellness consultation, has collaborated with a ... will bridge the knowledge gap experienced by parents and bring advice from parenting ...
(Date:11/27/2015)... Chicago, IL (PRWEB) , ... November 27, 2015 ... ... some of the largest, most successful and prominent nonprofit healthcare organizations in the ... and governance involvement with various organizations, and helped advance the healthcare industry as ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage ... style concert posters. This is one of Joplin's most famous and beautiful concert posters. ... University of Michigan in Ann Arbor. The According to Hawley, "It is hard to ...
Breaking Medicine News(10 mins):